文献速递肝病

振动控制瞬时弹性成像肝硬度20%变化对肝脏相关结局的影响:系统综述与Meta分析

Impact of 20% Change in Vibration-Controlled Transient Elastography-Measured Liver Stiffness on Liver-Related Outcomes: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-01-12

该系统综述与Meta分析纳入7项观察性研究、24,557例患者,评估振动控制瞬时弹性成像(VCTE)肝硬度测量(LSM)动态变化与肝脏相关事件(LRE)风险的关联。中位随访52.8个月,非代偿性进展者LRE风险显著升高(RR 6.02),代偿性进展者风险升高但无统计学意义(RR 1.64),代偿性逆转者LRE风险显著降低(RR 0.18)。

要点

  • 非cACLD进展者LRE风险显著升高(RR 6.02,95%CI 4.22-8.59)。
  • cACLD逆转者LRE风险显著降低(RR 0.18,95%CI 0.13-0.25)。
  • cACLD进展者LRE风险升高但无统计学意义(RR 1.64,95%CI 0.56-4.81)。

核心结论

  • 非cACLD进展者的LSM动态变化与LRE风险显著升高相关,cACLD逆转者与LRE风险显著降低相关。
  • 系列LSM测量可能有助于慢性肝病监测和作为临床试验终点。

研究设计与样本

  • 系统综述与Meta分析,纳入7项观察性研究,共24,557例接受多次LSM的患者。
  • 中位随访52.8个月。
  • 临床显著LSM变化定义:cACLD进展者(随访LSM较基线增加≥20%且基线LSM≥10 kPa);非cACLD进展者(随访LSM≥10 kPa且基线LSM<10 kPa);cACLD逆转者(随访LSM<10 kPa且基线LSM≥10 kPa,或随访LSM较基线降低≥20%且随访LSM<20 kPa)。

主要发现

  • cACLD进展者LRE风险17.9% vs 非进展者6.5%(RR 1.64,95%CI 0.56-4.81),差异无统计学意义。
  • 非cACLD进展者LRE风险5.7% vs 非进展者0.4%(RR 6.02,95%CI 4.22-8.59),差异有统计学意义。
  • cACLD逆转者LRE风险2.2% vs 非逆转者9%(RR 0.18,95%CI 0.13-0.25),差异有统计学意义。
  • 代谢功能障碍相关脂肪性肝病亚组分析显示类似结果。

关键数值与推荐

  • cACLD进展:随访LSM较基线增加≥20%且基线LSM≥10 kPa。
  • 非cACLD进展:随访LSM≥10 kPa且基线LSM<10 kPa。
  • cACLD逆转:随访LSM<10 kPa且基线LSM≥10 kPa,或随访LSM较基线降低≥20%且随访LSM<20 kPa。

临床怎么用

  • 对cACLD患者系列LSM监测,LSM逆转提示LRE风险显著降低。
  • 非cACLD患者LSM进展至≥10 kPa提示LRE风险显著升高。
  • LSM动态变化可作为慢性肝病监测和临床试验终点的潜在指标。

局限性

  • 纳入研究为观察性研究。
  • cACLD进展者LRE风险升高无统计学意义(95%CI宽,0.56-4.81)。
  • 需前瞻性纵向研究评估LSM变化是否与患者结局改善相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prognostic value of dynamic liver stiffness measurement (LSM) changes via vibration-controlled transient elastography in predicting liver-related events (LREs) for patients with compensated advanced chronic liver disease (cACLD) and no-cACLD remains unclear. METHODS: We conducted a systematic review and meta-analysis of observational studies evaluating LRE risk in patients with ACLD and multiple LSMs. Clinically significant LSM changes were defined as: cACLD progressors (follow-up LSM [fuLSM] ≥20% increase with baseline LSM [bLSM] ≥10 kPa); no cACLD progressors (fuLSM ≥10 kPa, bLSM <10 kPa); cACLD regressors (fuLSM <10 kPa with bLSM ≥10 kPa or fuLSM ≥20% decrease with fuLSM <20 kPa). Relative risks (RRs) with 95% confidence intervals (CIs) were calculated. RESULTS: Analysis of 24,557 patients from 7 studies revealed significant associations between dynamic LSM changes and LRE risk after a median follow-up of 52.8 months. cACLD progressors showed higher, although not statistically significant, LRE risk vs non-progressors (17.9% vs 6.5%; RR, 1.64; 95% CI, 0.56-4.81). No-cACLD progressors demonstrated significantly increased LRE risk compared with non-progressors (5.7% vs 0.4%; RR, 6.02; 95% CI, 4.22-8.59). Conversely, cACLD regressors exhibited significantly reduced LRE risk vs non-regressors (2.2% vs 9%; RR, 0.18; 95% CI, 0.13-0.25). Subgroup analysis in metabolic dysfunction-associated steatotic liver disease revealed similar results. CONCLUSIONS: Dynamic LSM changes in no-cACLD progressors and cACLD regressors are significantly associated with increased and decreased LRE risk, respectively. These findings highlight the potential of serial LSM measurements for monitoring chronic liver disease and for clinical trial endpoints. Prospective longitudinal studies are needed to evaluate if changes in LSM measurements over time are linked to improved patient outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ouranos K, Michael M, Mylona EK, et al. Impact of 20% Change in Vibration-Controlled Transient Elastography-Measured Liver Stiffness on Liver-Related Outcomes: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 41534760. doi:10.1016/j.cgh.2025.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。